614-86-8

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Dihydroxycinnamic acid is used as a pharmaceutical compound for its antioxidant and anti-inflammatory properties. It is being researched for its potential use in the development of drugs and dietary supplements that can help reduce inflammation and protect against free radical damage, potentially providing protection against certain diseases.
Used in Dietary Supplements:
2,4-Dihydroxycinnamic acid is used as an ingredient in dietary supplements for its health-promoting properties. It is believed to offer various benefits, such as reducing inflammation, protecting against free radical damage, and potentially providing protection against certain diseases. Its antioxidant properties make it a valuable addition to dietary supplements aimed at promoting overall health and well-being.
Used in Food and Beverage Industry:
2,4-Dihydroxycinnamic acid is used as a natural antioxidant in the food and beverage industry. It is commonly found in coffee, fruits, vegetables, and herbs, and can be used to extend the shelf life of these products by protecting them from oxidation. Its presence in these foods and beverages also contributes to their health-promoting properties.
Used in Cosmetics Industry:
2,4-Dihydroxycinnamic acid is used as an ingredient in cosmetics for its antioxidant and anti-inflammatory properties. It can be incorporated into skincare products to help protect the skin from free radical damage and reduce inflammation, potentially improving skin health and appearance.
Used in Agricultural Industry:
2,4-Dihydroxycinnamic acid can be used in the agricultural industry as a natural pesticide or growth promoter. Its antioxidant and anti-inflammatory properties may help protect plants from stress and promote healthy growth. Additionally, its presence in various plant sources can contribute to the overall health and quality of the crops.

InChI:InChI=1/C9H8O4/c10-7-3-1-6(8(11)5-7)2-4-9(12)13/h1-5,10-11H,(H,12,13)/p-1/b4-2+

Upstream product

• 93-35-6 7-hydroxy-2H-chromen-2-one 
• 10387-49-2 7-acetyloxycoumarin 
• 141-82-2 malonic acid 
• 95-01-2 2,4-Dihydroxybenzaldehyde 
• 6972-61-8 2,4-dimethoxycinnamic acid 

Relevant academic research and scientific papers

Synthesis, cytotoxicity and molecular modelling studies of new phenylcinnamide derivatives as potent inhibitors of cholinesterases

The present study reports the synthesis of cinnamide derivatives and their biological activity as inhibitors of both cholinesterases and anticancer agents. Controlled inhibition of brain acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) may slow neurodegeneration in Alzheimer's diseases (AD). The anticholinesterase activity of phenylcinnamide derivatives was determined against Electric Eel acetylcholinesterase (EeAChE) and horse serum butyrylcholinesterase (hBChE) and some of the compounds appeared as moderately potent inhibitors of EeAChE and hBChE. The compound 3-(2-(Benzyloxy)phenyl)-N- (3,4,5-trimethoxyphenyl)acrylamide (3i) showed maximum activity against EeAChE with an IC50 0.29 ± 0.21 μM whereas 3-(2-chloro-6- nitrophenyl)-N-(3,4,5-trimethoxyphenyl)acrylamide (3k) was proved to be the most potent inhibitor of hBChE having IC50 1.18 ± 1.31 μM. To better understand the enzyme-inhibitor interaction of the most active compounds toward cholinesterases, molecular modelling studies were carried out on high-resolution crystallographic structures. The anticancer effects of synthesized compounds were also evaluated against cancer cell line (lung carcinoma). The compounds may be useful leads for the design of a new class of anticancer drugs for the treatment of cancer and cholinesterase inhibitors for Alzheimer's disease (AD).

Curcumin recognizes a unique binding site of tubulin

Although curcumin is known for its anticarcinogenic properties, the exact mechanism of its action or the identity of the target receptor is not completely understood. Studies on a series of curcumin analogues, synthesized to investigate their tubulin binding affinities and tubulin self-assembly inhibition, showed that: (i) curcumin acts as a bifunctional ligand, (ii) analogues with substitution at the diketone and acetylation of the terminal phenolic groups of curcumin are less effective, (iii) a benzylidiene derivative, compound 7, is more effective than curcumin in inhibiting tubulin self-assembly. Cell-based studies also showed compound 7 to be more effective than curcumin. Using fluorescence spectroscopy we show that curcumin binds tubulin 32 ? away from the colchicine-binding site. Docking studies also suggests that the curcumin-binding site to be close to the vinblastine-binding site. Structure-activity studies suggest that the tridented nature of compound 7 is responsible for its higher affinity for tubulin compared to curcumin.